article thumbnail

The Composition and Value of a Portfolio Analysis

Camargo

For example, streamlined programs can be limited to literature searches, nonclinical studies, demonstration of bioequivalence to an approved product, or a combination of nonclinical and bioequivalence studies, and their relatively low costs may be appealing. Biowaiver Eligibility.

article thumbnail

How PK Modeling Can Inform Sample Size Estimation and Dose Selection for Your Product

Camargo

Pharmacokinetics (PK) and bioequivalence (BE) studies serve as the foundation of determining the fate of drug products. The results of the population analysis reveal the average relative bioavailability of the test to reference. The comparison of relative bioavailability based on simulated data then indicates if BE can be achieved.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

XTalks

The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. This regulatory strategy leverages bioequivalence studies to expedite approval, positioning Gelteq’s gel as an alternative to traditional oral delivery forms.

article thumbnail

FDA Releases Draft Guidance on Essential Drug Delivery Outputs

FDA Law Blog

Design validation may be covered by clinical studies, pharmacokinetic/pharmacodynamic or bioequivalence/bioavailability studies, literature, simulated bench testing, and/or anthropometric data and should include endpoints that have the capability of validating device performance.

article thumbnail

In the News: June 2021 Regulatory and Development Updates

Camargo

In June, the FDA issued an updated (draft) guidance titled “ Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies.” FDA Publishes Draft Guidance on Adverse Drug Experience Reporting for INDs and BA/BE Studies .

article thumbnail

Can a CRL Be Final Agency Action: One Step Closer to Finding Out

FDA Law Blog

Circuit, their client Nostrum Laboratories sought judicial review after FDA agreed to allow a certain type of study to establish bioequivalence for generic theophylline, Nostrum conducted those studies, and then FDA issued a CRL asking for new, time-consuming, expensive studies of a different sort.

article thumbnail

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting

The Pharma Data

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO ® (deutetrabenazine) tablets The U.S. Bioequivalence and relative bioavailability were established between the once-daily and twice-daily tablet formulations, with no new safety findings emerging.